IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Results of Operations and Financial Condition
Item 9.01 Results of Operations and Financial Condition.

On August3, 2017,Ironwood Pharmaceuticals,Inc. issued a press release containing an update on its recent business activities as well as those for the quarter ended June30, 2017. A copy of the press release is furnished as Exhibit99.1 and is incorporated herein by reference.

The press release is being furnished to Item 9.01 of this Current Report on Form8-K and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Ironwood Pharmaceuticals,Inc. Press Release dated August3, 2017


IRONWOOD PHARMACEUTICALS INC Exhibit
EX-99.1 2 a17-18720_3ex99d1.htm EX-99.1 Exhibit 99.1           FOR IMMEDIATE RELEASE     Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update   –LINZESS® (linaclotide) expanded IBS-C/CIC branded prescription market leadership in 2Q 2017 with 19% growth in volume year-over-year and $168 million in U.S. net sales –   – Positive IW-3718 Phase IIb top-line data in uncontrolled GERD support advancement into Phase III –   – Multiple additional catalysts expected in 2H 2017,…
To view the full exhibit click here

About IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.